These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Multicentre dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging. Saini S; Sharma R; Baron RL; Turner DA; Ros PR; Hahn PF; Small WC; Delange EE; Stillman AE; Edelman RR; Runge VM; Outwater EK Clin Radiol; 2000 Sep; 55(9):690-5. PubMed ID: 10988047 [TBL] [Abstract][Full Text] [Related]
9. MR imaging with i.v. superparamagnetic iron oxide: efficacy in the detection of focal hepatic lesions. Winter TC; Freeny PC; Nghiem HV; Mack LA; Patten RM; Thomas CR; Elliott S AJR Am J Roentgenol; 1993 Dec; 161(6):1191-8. PubMed ID: 8249724 [TBL] [Abstract][Full Text] [Related]
10. Detection of malignant hepatic tumors with ferumoxide-enhanced MR imaging: usefulness of multishot and single-shot fast spin echo sequences. Goshima S; Kanematsu M; Matsuo M; Murakami T; Hori M; Takamura M; Kondo H; Kako N; Moriyama N; Nakamura H; Hoshi H Magn Reson Imaging; 2004 Apr; 22(3):379-88. PubMed ID: 15062933 [TBL] [Abstract][Full Text] [Related]
11. Mangafodipir trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: is delayed imaging useful? Chung JJ; Kim MJ; Kim KW J Magn Reson Imaging; 2006 May; 23(5):706-11. PubMed ID: 16565954 [TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma in cirrhotic livers: detection with unenhanced and iron oxide-enhanced MR imaging. Yamamoto H; Yamashita Y; Yoshimatsu S; Baba Y; Hatanaka Y; Murakami R; Nishiharu T; Takahashi M; Higashida Y; Moribe N Radiology; 1995 Apr; 195(1):106-12. PubMed ID: 7892448 [TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. Ward J; Guthrie JA; Scott DJ; Atchley J; Wilson D; Davies MH; Wyatt JI; Robinson PJ Radiology; 2000 Jul; 216(1):154-62. PubMed ID: 10887242 [TBL] [Abstract][Full Text] [Related]
14. [Clinical application of AMI-25 (superparamagnetic iron oxide) for the MR imaging of hepatic tumors: a multicenter clinical phase III study]. Yoshikawa K; Sasaki Y; Ogawa N; Sakuma S Nihon Igaku Hoshasen Gakkai Zasshi; 1994 Feb; 54(2):137-53. PubMed ID: 8121779 [TBL] [Abstract][Full Text] [Related]
15. Benign hepatocellular tumors: MRI after superparamagnetic iron oxide administration. Grandin C; Van Beers BE; Robert A; Gigot JF; Geubel A; Pringot J J Comput Assist Tomogr; 1995; 19(3):412-8. PubMed ID: 7790551 [TBL] [Abstract][Full Text] [Related]
16. [The MR tomography of focal liver lesions with the superparamagnetic contrast agent AMI-25 at 1.5 tesla]. Duda SH; Laniado M; Kopp AF; Grönewäller E; Aicher KP; Pavone P; Jehle E; Claussen CD Rofo; 1994 Jan; 160(1):46-51. PubMed ID: 8305692 [TBL] [Abstract][Full Text] [Related]
17. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Ros PR; Freeny PC; Harms SE; Seltzer SE; Davis PL; Chan TW; Stillman AE; Muroff LR; Runge VM; Nissenbaum MA Radiology; 1995 Aug; 196(2):481-8. PubMed ID: 7617864 [TBL] [Abstract][Full Text] [Related]
18. European clinical experience with Endorem. A new contrast agent for liver MRI in 1000 patients. Chachuat A; Bonnemain B Radiologe; 1995 Nov; 35(11 Suppl 2):S274-6. PubMed ID: 8588035 [No Abstract] [Full Text] [Related]
19. Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. Bellin MF; Zaim S; Auberton E; Sarfati G; Duron JJ; Khayat D; Grellet J Radiology; 1994 Dec; 193(3):657-63. PubMed ID: 7972804 [TBL] [Abstract][Full Text] [Related]
20. Superparamagnetic iron oxide-enhanced MR imaging for focal hepatic lesions: a comparison with CT during arterioportography plus CT during hepatic arteriography. Tanimoto A; Wakabayashi G; Shinmoto H; Nakatsuka S; Okuda S; Kuribayashi S J Gastroenterol; 2005 Apr; 40(4):371-80. PubMed ID: 15870974 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]